Cargando…

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Ensitrelvir is a novel selective inhibitor of the 3C-like protease of SARS-CoV-2, which is essential for viral replication. This phase 1 study of ensitrelvir assessed its safety, tolerability, and pharmacokinetics of single (part 1, n = 50) and multiple (part 2, n = 33) ascending oral doses. Effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Ryosuke, Sonoyama, Takuhiro, Fukuhara, Takahiro, Kuwata, Aya, Matsuo, Yumiko, Kubota, Ryuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/ https://www.ncbi.nlm.nih.gov/pubmed/36094202 http://dx.doi.org/10.1128/aac.00632-22

Ejemplares similares

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
por: Vaddady, Pavan, et al.
Publicado: (2020)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019)

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
por: Painter, Wendy P., et al.
Publicado: (2021)

A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques
por: Su, Jonathan T., et al.
Publicado: (2020)

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses
por: Ekins, Sean, et al.
Publicado: (2020)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
por: Hung, Hui-Chen, et al.
Publicado: (2020)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals
por: de León, Patricia, et al.
Publicado: (2023)

Original Chemical Series of Pyrimidine Biosynthesis Inhibitors That Boost the Antiviral Interferon Response
por: Lucas-Hourani, Marianne, et al.
Publicado: (2017)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
por: Xu, Yili, et al.
Publicado: (2021)

Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
por: Kuo, Chih-Jung, et al.
Publicado: (2021)

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
por: Amberg, Sean M., et al.
Publicado: (2022)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
por: Lingscheid, Tilman, et al.
Publicado: (2022)

A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses
por: Meunier, Thomas, et al.
Publicado: (2022)

Pharmacological Elevation of Cellular Dihydrosphingomyelin Provides a Novel Antiviral Strategy against West Nile Virus Infection
por: Jiménez de Oya, Nereida, et al.
Publicado: (2023)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
por: Innes, Steve, et al.
Publicado: (2018)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years
por: Luo, Man, et al.
Publicado: (2016)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
por: Tong, Xiao, et al.
Publicado: (2023)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
por: Kankam, Martin K., et al.
Publicado: (2021)

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
por: Nowicka-Sans, Beata, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sp85csod7i0rkcvmnukq1aq7ab